<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="45942">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02508155</url>
  </required_header>
  <id_info>
    <org_study_id>D5680C00001</org_study_id>
    <nct_id>NCT02508155</nct_id>
  </id_info>
  <brief_title>A Study of MEDI7352 in Painful Osteoarthritis of the Knee</brief_title>
  <official_title>A Randomised, Double-Blind, Placebo-Controlled, Single- and Multiple-Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MEDI7352 in Subjects With Painful Osteoarthritis of the Knee.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety, drug levels and effects on the body of
      MEDI7352, in subjects with painful osteoarthritis of the knee.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An interleaved SAD/MAD Study to assess the safety, tolerability, pharmacokinetics and
      pharmacodynamics of MEDI7352 in subjects with painful osteoarthritis of the knee.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2015</start_date>
  <completion_date type="Anticipated">June 2017</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Participant, Care Provider, Investigator</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with Adverse Events as a Measure of Safety and Tolerability of MEDI7352</measure>
    <time_frame>All visits from screening up to 56 days post single dose/84 days post multiple dose</time_frame>
    <description>Adverse events, serious adverse events,</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with Adverse Events as a Measure of Safety and Tolerability of MEDI7352</measure>
    <time_frame>All visits from screening up to 56 days post single dose/84 days post multiple dose</time_frame>
    <description>Clinical laboratory assessments (serum chemistry, hematology, urinalysis)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with Adverse Events as a Measure of Safety and Tolerability of MEDI7352</measure>
    <time_frame>All visits from screening up to 56 days post single dose/84 days post multiple dose</time_frame>
    <description>12 Lead electrocardiogram (including QTc, QRS, PR intervals and ventricular rate)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with Adverse Events as a Measure of Safety and Tolerability of MEDI7352</measure>
    <time_frame>All visits from screening up to 56 days post single dose/84 days post multiple dose</time_frame>
    <description>Vital signs (systolic and diastolic BP), heart rate</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with Adverse Events as a Measure of Safety and Tolerability of MEDI7352</measure>
    <time_frame>At screening and at follow up visit.</time_frame>
    <description>MRI</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma drug concentration versus time curves for MEDI7352</measure>
    <time_frame>All visits from screening up to 56 days post single dose/84 days post multiple dose</time_frame>
    <description>Area under the plasma drug concentration versus time curves from zero to infinity and to last observation (AUC 0-inf; AUC 0-t).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed plasma drug concentration (Cmax) of MEDI7352</measure>
    <time_frame>All visits from screening up to 56 days post single dose/84 days post multiple dose</time_frame>
    <description>Maximum observed plasma drug concentration (Cmax).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to maximum observed plasma drug concentration (Tmax) of MEDI7352</measure>
    <time_frame>All visits from screening up to 56 days post single dose/84 days post multiple dose</time_frame>
    <description>Time to maximum observed plasma drug concentration (Tmax).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal plasma elimination half-life (t1/2) of MEDI7352</measure>
    <time_frame>All visits from screening up to 56 days post single dose/84 days post multiple dose</time_frame>
    <description>Terminal plasma elimination half-life (t1/2).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent clearance (CL/F).</measure>
    <time_frame>All visits from screening up to 56 days post single dose/84 days post multiple dose</time_frame>
    <description>Apparent clearance (CL/F).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The presence of anti-drug antibodies (ADAs) to MEDI7352</measure>
    <time_frame>All visits from screening up to 56 days post single dose/84 days post multiple dose</time_frame>
    <description>The incidence of anti-drug antibodies (a measure of the body's immune response to the drug).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Numerical Rating Scale (NRS)</measure>
    <time_frame>All visits from screening up to 56 days post single dose/84 days post multiple dose</time_frame>
    <description>Numerical Rating Scale (NRS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain subscale, stiffness subscale and function subscale.</measure>
    <time_frame>All visits from screening up to 56 days post single dose/84 days post multiple dose</time_frame>
    <description>Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain subscale, stiffness subscale and function subscale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients' Global Impression of Change Scale (PGIC)</measure>
    <time_frame>All visits from screening up to 56 days post single dose/84 days post multiple dose</time_frame>
    <description>Patients' Global Impression of Change Scale (PGIC)</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Chronic Pain</condition>
  <arm_group>
    <arm_group_label>MEDI7352 IV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Up to 10 cohorts of subjects are planned to be dosed by IV infusion, with single and multiple ascending doses.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IV Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Up to 10 cohorts of subjects are planned to be dosed by IV infusion, with single and multiple ascending doses.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MEDI7352 Subcutaneous Injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 cohorts of subjects are planned to be dosed by subcutaneous injection, one single ascending dose cohort and one multiple ascending dose cohort</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subcutaneous Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>2 cohorts of subjects are planned to be dosed by subcutaneous injection, one single ascending dose cohort and one multiple ascending dose cohort.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MEDI7352 for IV infusion</intervention_name>
    <description>MEDI7352 for IV infusion</description>
    <arm_group_label>MEDI7352 IV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo for IV infusion</intervention_name>
    <description>IV Placebo infusion</description>
    <arm_group_label>IV Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MEDI7352 for Subcutaneous Injection</intervention_name>
    <description>MEDI7352 for subcutaneous injection</description>
    <arm_group_label>MEDI7352 Subcutaneous Injection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo for Subcutaneous Injection</intervention_name>
    <description>Subcutaneous Placebo Injection</description>
    <arm_group_label>Subcutaneous Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female subjects with painful osteoarthritis (OA) of the knee. Female
             subjects must be postmenopausal or surgically sterile.

          -  Body weight between 50kg and 145kg

          -  Willing and able to comply with the requirements of the protocol

        Exclusion Criteria:

          -  Current treatment with another biologic therapeutic agent

          -  Current of historical diagnosis of RA

          -  Current diagnosis of an immunological condition that is associated with another form
             of arthritis in addition to OA, including traumatic arthritis or a seronegative
             spondyloarthropathy

          -  At risk of destructive arthropathy, including Rapidly Progressive Osteoarthritis
             (RPOA), osteonecrosis, spontaneous osteonecrosis of the knee, subchondral
             insufficiency fractures, hip dislocation and pathological fracture

          -  Presence of clinically significant neuropathy or other clinically significant
             disorder involving abnormal peripheral sensation.

          -  Current serious or unstable clinically important illness.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Bell, MB BCh BAO MRCGP FFPM</last_name>
    <role>Principal Investigator</role>
    <affiliation>Biokinetics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>AstraZeneca Clinical Study Information Center</last_name>
    <phone>1-877-240-9479</phone>
    <email>information.center@astrazeneca.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>GoÌˆteborg</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Belfast</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>February 6, 2017</lastchanged_date>
  <firstreceived_date>July 2, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Chronic Pain</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
